Gleason grading system

Last updated
Gleason grading system
Gleasonscore.jpg
Gleason grade — Lower grades are associated with small, closely packed glands. Cells spread out and lose glandular architecture as grade increases. Gleason score is calculated from grade as described in the text.

The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. [1]

Contents

Cancers with a higher Gleason score are more aggressive and have a worse prognosis. Pathological scores range from 2 to 10, with higher numbers indicating greater risks and higher mortality. The system is widely accepted and used for clinical decision making even as it is recognised that certain biomarkers, like ACP1 expression, might yield higher predictive value for future disease course. [2]

The histopathologic diagnosis of prostate cancer has implications for the possibility and methodology of Gleason scoring. [3] For example, it is not recommended in signet-ring adenocarcinoma or urothelial carcinoma of the prostate, and the scoring should discount the foamy cytoplasms seen in foamy gland carcinoma. [3]

A total score is calculated based on how cells look under a microscope, with the first half of the score based on the dominant, or most common cell morphology (scored 1 to 5), and the second half based on the non-dominant cell pattern with the highest grade (scored 1 to 5). These two numbers are then combined to produce a total score for the cancer.

Specimens and processing

Most often, a urologist or radiologist will remove a cylindrical sample (biopsy) of prostate tissue through the rectum (or, sometimes the perineum), using hollow needles, and biomedical scientists in a histology laboratory prepare microscope slides for H&E staining and immunohistochemistry for diagnosis by a pathologist. If the prostate is surgically removed, a pathologist will slice the prostate for a final examination.[ citation needed ]

Histologic patterns

Gleason pattern 3. H&E stain. Gleason 3.jpg
Gleason pattern 3. H&E stain.
Gleason pattern 4. H&E stain. Prostate cancer with Gleason pattern 4 low mag.jpg
Gleason pattern 4. H&E stain.
Gleason pattern 4 (left of image) and Gleason pattern 5 (right of image). H&E stain. Gleason 4 and 5 intermed mag.jpg
Gleason pattern 4 (left of image) and Gleason pattern 5 (right of image). H&E stain.

A pathologist microscopically examines the biopsy specimen for certain "Gleason" patterns. These Gleason patterns are associated with the following features:[ citation needed ]

In the present form of the Gleason system, prostate cancer of Gleason patterns 1 and 2 are rarely seen. Gleason pattern 3 is by far the most common.[ citation needed ]

Primary, secondary and tertiary grades

After analyzing the tissue samples, the pathologist then assigns a grade to the observed patterns of the tumor specimen.[ citation needed ]

Scores and prognoses

The pathologist then sums the pattern-number of the primary and secondary grades to obtain the final Gleason score. If only two patterns are seen, the first number of the score is that of the tumor's primary grade while the second number is that of the secondary grade, as described in the previous section. If three patterns are seen, the first number of the score would be the primary grade and the second number the pattern with the highest grade.

For example, if the primary tumor grade was 2 and the secondary tumor grade was 3 but some cells were found to be grade 4, the Gleason score would be 2+4=6. This is a slight change from the pre-2005 Gleason system where the second number was the secondary grade (i.e., the grade of the second-most common cell line pattern). [4]

Key- blue: Gleason pattern 3 region, yellow: Gleason pattern 4 region, red: Gleason pattern 5 region


Gleason scores range from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the least-differentiated tumors. Gleason scores have often been categorized into groups that show similar biologic behavior: low-grade (well-differentiated), intermediate-grade, moderate to poorly differentiated or high-grade. [5]

More recently, an investigation of the Johns Hopkins Radical Prostatectomy Database (1982-2011) led to the proposed reporting of Gleason grades and prognostic grade groups as:

Prostate cancers with a Gleason score ≤ 6 usually have rather good prognoses.

Grading mechanism

The Gleason grade of architectural pattern is sometimes referred to as the Gleason architectural pattern.[ citation needed ]

The Gleason grade is based on tissue architectural patterns rather than purely cytological changes. These tissue patterns are classified into 5 grades, numbered 1 though 5. Lower numbers indicate more differentiation, with pattern 5 being the least differentiated. [4] [7] Differentiation is the degree to which the tissue, in this case the tumor, resembles native tissue. Greater resemblance (lower grade) is typically associated with a better prognosis.[ citation needed ]

However, the Gleason score is not simply the highest grade (least differentiated) pattern within the tumor. Rather, it is a combination of the most two most frequent patterns seen. This recognizes that prostatic carcinomas have multiple patterns and that prognosis is more accurately determined by adding the scores of the two most prevalent patterns. Using this system, the grades of the most prevalent and second most prevalent patterns (if at least 5% of the total), are added together to yield the overall Gleason score. [4] [7]

For example, if the most prevalent pattern/grade is 2, and the second most prevalent grade is 1, then the Gleason score is 2+1=3. If the neoplasm has only one pattern, the grade of that pattern is doubled to obtain the score. For example, if a tumor is entirely grade 1, the Gleason score would be 1+1=2. The most differentiated tumor would have the lowest score, Gleason 2 (1+1), while the most undifferentiated neoplasm (not resembling native prostate tissue) would have the highest score, Gleason 10 (5+5). Gleason scores range from 2 to 10; by definition there is no score of 0 or 1. [4] [7]

Cytological differences between normal prostate and neoplastic glands are evident in changes to the typical two cell layers of the gland. In prostatic adenocarcinoma, the basal (bottom, usually cuboidal type) cell layer is lost, with only the top layer (usually columnar to pseudostratified) remaining.[ citation needed ]

Score descriptions

Using this system, the most well-differentiated tumors have a Gleason score/grade of 2, and the least-differentiated tumors a score of 10. Range by definition is from 2-10, with architectural type from 1-5, and always added together or doubled, as described above. Gleason scores are often grouped together, based on similar behaviour: Grade 2-4 as well-differentiated, Grade 5-6 as intermediately-differentiated, Grade 7 as moderately to poorly differentiated (either 3+4=7, where the majority is pattern 3, or 4+3=7 in which pattern 4 dominates and indicates less differentiation., [6] and Grade 8-10 as "high-grade." [4] [7]

Gleason 1

Gleason pattern 1 is the most well-differentiated tumor pattern. It is a well-defined nodule of single/separate, closely/densely packed, back-to-back gland pattern that does not invade into adjacent healthy prostatic tissue. The glands are round to oval shaped and proportionally large, compared to Gleason pattern 3 tumors, and are approximately equal in size and shape to one another. [4] [7]

Gleason 2

Gleason 2 is fairly well-circumscribed nodules of single, separate glands. However, the glands are looser in arrangement and not as uniform as in pattern 1. Minimal invasion by neoplastic glands into the surrounding healthy prostate tissue may be seen. Similar to Gleason 1, the glands are usually larger than those of Gleason 3 patterns, and are round to oval in shape. Thus the main difference between Gleason 1 and 2 is the density of packing of the glands seen; invasion is possible in Gleason 2, but by definition not in Gleason 1. [4] [7]

Gleason 3

Gleason 3 is a clearly infiltrative neoplasm, with extension into adjacent healthy prostate tissue. The glands alternate in size and shape, and are often long/angular. They are usually small/micro-glandular in comparison to Gleason 1 or 2 grades. However, some may be medium to large in size. The small glands of Gleason 3, in comparison to the small and poorly defined glands of pattern 4, are distinct glandular units. Mentally you could draw a circle around each of the glandular units in Gleason 3. [4] [7]

Gleason 4

Gleason pattern 4 glands are no longer single/separated glands like those seen in patterns 1-3. They look fused together, difficult to distinguish, with rare lumen formation vs Gleason 1-3 which usually all have open lumens (spaces) within the glands, or can be cribriform-(resembling the cribriform plate/similar to a sieve: an item with many perforations). Fused glands are chains, nests, or groups of glands that are no longer entirely separated by stroma-(connective tissue that normally separates individual glands in this case). Fused glands contain occasional stroma giving the appearance of "partial" separation of the glands. Due to this partial separation, fused glands sometimes have a scalloped (think looking at a slice of bread with bite taken out of it) appearance at their edges. [4] [7]

Gleason 5

Neoplasms have no glandular differentiation (thus not resembling normal prostate tissue at all). It is composed of sheets (groups of cells almost planar in appearance (like the top of a box), solid cords (group of cells in a rope like fashion running through other tissue/cell patterns seen), or individual cells. You should not see round glands with lumenal spaces that can be seen in the other types that resemble more the normal prostate gland appearance. [4] [7]

Prognosis

Gleason scores 2-4 are typically found in smaller tumors located in the transitional zone (around the urethra). These are typically found incidentally on surgery for benign prostatic hyperplasia, which is not itself a precursor lesion for prostatic carcinoma. [4]

The majority of treatable/treated cancers are of Gleason scores 5-7 and are detected due to biopsy after abnormal digital rectal exam or prostate specific antigen evaluation. The cancer is typically located in the peripheral zone usually the posterior portion, explaining the rationale of performing the digital rectal exam.[ citation needed ]

Tumors with Gleason scores 8-10 tend to be advanced neoplasms that are unlikely to be cured. Although some evidence suggests that prostate cancers will become more aggressive over time, Gleason scores typically remain stable for several years. [4]

The Gleason scores then become part of the TNM or Whitmore-Jewett prostate cancer staging system to provide prognosis.

History

The Gleason scoring system takes its name from Donald Gleason, a pathologist at the Minneapolis Veterans Affairs Hospital, who developed it with colleagues at that facility in the 1960s. [8] [9] In 2005 the International Society of Urological Pathology altered the Gleason system, refining the criteria and changing the attribution of certain patterns. [4] It has been shown that this "modified Gleason score" has higher performance than the original one, and is currently assumed standard in urological pathology. In this form, it remains an important tool. [10]

However, problematic aspects of the original Gleason grading system still characterize the 2005 revision. The predominant lowest score assigned is Gleason 3+3 = 6. Patients who are told their Gleason score is 6 out of 10 may interpret that they have a more aggressive intermediate cancer and experience greater anxiety. [11] More importantly, some classification systems fail to clearly distinguish between Gleason 3+4 = 7 and Gleason 4+3 = 7, with the latter having a worse prognosis.

Therefore, in 2014 an international multidisciplinary conference was convened to revise the 2005 system. A 5-point Gleason Grade grouping similar to those such as PI-RADS used with prostate MRI evaluations was proposed to denote prognostically distinct stratification. Grade 1 would indicate the lowest-risk cancer while Grade 5 would indicate the most aggressive disease. The system was tested and validated against 20,000 prostatectomy specimens and at least 16,000 biopsy samples.

The majority of conference participants concurred on the superiority of the scale over the 2005 Gleason grading system, pointing to the likelihood that overtreatment could be avoided for those patients whose cancer was assigned Grade 1. The World Health Organization's 2016 edition of Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs has accepted the 2014 system, which can be used in conjunction with the 2005 Gleason system. [12]

See also

Related Research Articles

<span class="mw-page-title-main">Prostate cancer</span> Male reproductive organ cancer

Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Early prostate cancer causes no symptoms. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is present, the pathologist assigns a Gleason score, and a higher score represents a more dangerous tumor. Medical imaging is performed to look for cancer that has spread outside the prostate. Based on the Gleason score, PSA levels, and imaging results, a cancer case is assigned a stage 1 to 4. Higher stage signifies a more advanced, more dangerous disease.

<span class="mw-page-title-main">Thyroid neoplasm</span> Medical condition

Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, or it can be a malignant neoplasm, such as papillary, follicular, medullary or anaplastic thyroid cancer. Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men. The estimated number of new cases of thyroid cancer in the United States in 2023 is 43,720 compared to only 2,120 deaths. Of all thyroid nodules discovered, only about 5 percent are cancerous, and under 3 percent of those result in fatalities.

<span class="mw-page-title-main">Adenocarcinoma</span> Medical condition

Adenocarcinoma is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both. Adenocarcinomas are part of the larger grouping of carcinomas, but are also sometimes called by more precise terms omitting the word, where these exist. Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name—however, esophageal adenocarcinoma does to distinguish it from the other common type of esophageal cancer, esophageal squamous cell carcinoma. Several of the most common forms of cancer are adenocarcinomas, and the various sorts of adenocarcinoma vary greatly in all their aspects, so that few useful generalizations can be made about them.

<span class="mw-page-title-main">Carcinoma</span> Malignancy that develops from epithelial cells

Carcinoma is a malignancy that develops from epithelial cells. Specifically, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that arises from cells originating in the endodermal, mesodermal or ectodermal germ layer during embryogenesis.

<span class="mw-page-title-main">Adenoma</span> Type of benign tumor

An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or both. Adenomas can grow from many glandular organs, including the adrenal glands, pituitary gland, thyroid, prostate, and others. Some adenomas grow from epithelial tissue in nonglandular areas but express glandular tissue structure. Although adenomas are benign, they should be treated as pre-cancerous. Over time adenomas may transform to become malignant, at which point they are called adenocarcinomas. Most adenomas do not transform. However, even though benign, they have the potential to cause serious health complications by compressing other structures and by producing large amounts of hormones in an unregulated, non-feedback-dependent manner. Some adenomas are too small to be seen macroscopically but can still cause clinical symptoms.

<span class="mw-page-title-main">Pseudomyxoma peritonei</span> Medical condition

Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells that produce abundant mucin or gelatinous ascites. The tumors cause fibrosis of tissues and impede digestion or organ function, and if left untreated, the tumors and mucin they produce will fill the abdominal cavity. This will result in compression of organs and will destroy the function of the colon, small intestine, stomach, or other organs. Prognosis with treatment in many cases is optimistic, but the disease is lethal if untreated, with death occurring via cachexia, bowel obstruction, or other types of complications.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

Prostate cancer staging is the process by which physicians categorize the risk of cancer having spread beyond the prostate, or equivalently, the probability of being cured with local therapies such as surgery or radiation. Once patients are placed in prognostic categories, this information can contribute to the selection of an optimal approach to treatment. Prostate cancer stage can be assessed by either clinical or pathological staging methods. Clinical staging usually occurs before the first treatment and tumour presence is determined through imaging and rectal examination, while pathological staging is done after treatment once a biopsy is performed or the prostate is removed by looking at the cell types within the sample.

<span class="mw-page-title-main">Grading (tumors)</span> Measure of the cell appearance in tumors and other neoplasms

In pathology, grading is a measure of the cell appearance in tumors and other neoplasms. Some pathology grading systems apply only to malignant neoplasms (cancer); others apply also to benign neoplasms. The neoplastic grading is a measure of cell anaplasia in the sampled tumor and is based on the resemblance of the tumor to the tissue of origin. Grading in cancer is distinguished from staging, which is a measure of the extent to which the cancer has spread.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Symptoms of urothelial carcinoma in the bladder include hematuria. Diagnosis includes urine analysis and imaging of the urinary tract (cystoscopy). Transitional cell carcinomas arise from the transitional epithelium, a tissue lining the inner surface of these hollow organs. When the term "urothelial" is used, it specifically refers to a carcinoma of the urothelium, meaning a transitional cell carcinomas of the urinary system.

<span class="mw-page-title-main">Salivary gland tumour</span> Medical condition

Salivary gland tumours, also known as mucous gland adenomas or neoplasms, are tumours that form in the tissues of salivary glands. The salivary glands are classified as major or minor. The major salivary glands consist of the parotid, submandibular, and sublingual glands. The minor salivary glands consist of 800 to 1000 small mucus-secreting glands located throughout the lining of the oral cavity. Patients with these types of tumours may be asymptomatic.

Comedocarcinoma is a kind of breast cancer that demonstrates comedonecrosis, which is the central necrosis of cancer cells within involved ducts. Comedocarcinomas are usually non-infiltrating and intraductal tumors, characterized as a comedo-type, high-grade ductal carcinoma in situ (DCIS). However, there have been accounts of comedocarcinoma which has then diversified into other cell types and developed into infiltrating (invasive) ductal carcinoma. Recurrence and survival rates differ for invasive breast cancer which has originated as comedocarcinoma compared with other types of cancer cells.

<span class="mw-page-title-main">High-grade prostatic intraepithelial neoplasia</span> Medical condition

High-grade prostatic intraepithelial neoplasia (HGPIN) is an abnormality of prostatic glands and believed to precede the development of prostate adenocarcinoma.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Perineural invasion</span> Biological process

In pathology, perineural invasion, abbreviated PNI, refers to the invasion of cancer to the space surrounding a nerve. It is common in head and neck cancer, prostate cancer and colorectal cancer.

Acinar adenocarcinoma is a histological subtype of gland-forming cancer that is diagnosed when cuboidal and/or columnar shaped malignant cells in the neoplastic tissue form acini and tubules. It is a common form of cancer occurring in the lung and prostate gland.

A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring. The most common histopathological subdiagnosis of prostate cancer is acinar adenocarcinoma, constituting 93% of prostate cancers. The most common form of acinar adenocarcinoma, in turn, is "adenocarcinoma, not otherwise specified", also termed conventional, or usual acinar adenocarcinoma.

<span class="mw-page-title-main">Histopathology of colorectal adenocarcinoma</span> Analysis of tissue from a biopsy or surgery to identify colorectal cancer characteristics

The histopathology of colorectal cancer of the adenocarcinoma type involves analysis of tissue taken from a biopsy or surgery. A pathology report contains a description of the microscopical characteristics of the tumor tissue, including both tumor cells and how the tumor invades into healthy tissues and finally if the tumor appears to be completely removed. The most common form of colon cancer is adenocarcinoma, constituting between 95% and 98% of all cases of colorectal cancer. Other, rarer types include lymphoma, adenosquamous and squamous cell carcinoma. Some subtypes have been found to be more aggressive.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

<span class="mw-page-title-main">Invasive cribriform carcinoma of the breast</span> Medical condition

Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer that accounts for 0.3% to 0.6% of all carcinomas in the breast. It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands. ICCB was first described by Dixon and colleagues in 1983 as a tumor that on microscopic histopathological inspection had a cribriform pattern, i.e. a tissue pattern consisting of numerous "Swiss cheese"-like open spaces and/or sieve-like small holes. The latest edition (2019) of the World Health Organization (2019) termed these lesions invasive cribriform carcinomas indicating that by definition they must have a component that invades out of their ducts of origin into adjacent tissues. In situ ductal cancers that have a cribriform histopathology are regarded as belonging to the group of ductal carcinoma in situ tumors.

References

  1. "Male Genital Pathology". The Internet Pathology Laboratory for Medical Education. The University of Utah, Eccles Health Sciences Library. Retrieved 2009-05-13.
  2. Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, et al. (April 2016). "Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential". European Urology. 69 (4): 710–719. doi:10.1016/j.eururo.2015.06.040. PMID   26159288.
  3. 1 2 Li J, Wang Z (February 2016). "The pathology of unusual subtypes of prostate cancer". Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 28 (1): 130–143. doi:10.3978/j.issn.1000-9604.2016.01.06. PMC   4779761 . PMID   27041935.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 Epstein JI, Allsbrook WC, Amin MB, Egevad LL (September 2005). "The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma". The American Journal of Surgical Pathology. 29 (9): 1228–1242. doi:10.1097/01.pas.0000173646.99337.b1. PMID   16096414. S2CID   7428768.
  5. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. Seventh ed: Elsevier Saunders; 2005.
  6. 1 2 Humphrey PA (March 2004). "Gleason grading and prognostic factors in carcinoma of the prostate". Modern Pathology. 17 (3): 292–306. doi: 10.1038/modpathol.3800054 . PMID   14976540.
  7. 1 2 3 4 5 6 7 8 9 10 Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU International. 2013;111(5):753-760.
  8. Albertsen, Peter C. (1 May 2006). "How to interpret Gleason score in contemporary biopsy". Urology Times. Archived from the original on 2006-11-23. (URL is live, but appear corrupted compared to archived version.)
  9. Gleason DF (1977). "The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma" . In Tannenbaum M (ed.). Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger. pp.  171–198. ISBN   0-8121-0546-X.
  10. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, et al. (May 2013). "Contemporary grading for prostate cancer: implications for patient care". European Urology. 63 (5): 892–901. doi:10.1016/j.eururo.2012.10.015. PMID   23092544.
  11. McCullough M (December 13, 2015). "More with early-stage prostate cancers choosing to wait and see before surgery" . The Philadelphia Inquirer. (related, from philly.com: 8 tell how they handle testing, anxiety of prostate cancer waiting)
  12. Sperling D. "Revisions of the Gleason grading system make it more accurate". Sperling Prostate Center. Retrieved 31 March 2016.